DJ Hardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy: Progress towards commissioning of first LIGHT
Hardman & Co Research
Hardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy:
Progress towards commissioning of first LIGHT
23-Oct-2020 / 14:25 GMT/BST
Hardman & Co Research: Progress towards commissioning of first LIGHT
Advanced Oncotherapy (AVO) was the topic of conversation when Dr Martin Hall
joined DirectorsTalk. Martin explains what's been happening with the company
lately, the potential advantages of LIGHT, how close we are to the first
system, how AVO is funding all the work and what investors and potential
investors can look forward to over the coming months.
Please click on the link below to listen to the interview:
https://vimeo.com/470092801 [1]
If you are interested in meeting the company, you can register your interest
here [2].
To contact us: Contact:
Hardman & Co Martin Hall mh@hardmanandco.com
35 New Broad Street
London +44 20 7194 7622
EC2M 1NH
www.hardmanandco.com
Follow us on Twitter
@HardmanandCo
Hardman & Co Research can still be accessed for free after MiFID II. Please
click here [3] to read the statement.
About Hardman & Co: For the past 25 years Hardman has been producing
specialist research designed to improve investors' understanding of
companies, sectors, industries and investment securities. Our analysts are
highly experienced in their sectors, and have often been highly rated by
professional investors for their knowledge. Our focus is to raise companies'
profiles across the UK and abroad with outstanding research, investor
engagement programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this is
clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed
representative of Capital Markets Strategy Ltd and is authorised and
regulated by the Financial Conduct Authority; our FCA registration number is
600843. Hardman Research Ltd is registered at Companies House with number
8256259.
Our research is provided for the use of the professional investment
community, market counterparties and sophisticated and high net worth
investors as defined in the rules of the regulatory bodies. It is not
intended to be made available to unsophisticated retail investors. Anyone
who is unsure of their categorisation should consult their professional
advisors. This research is neither an offer, nor a solicitation, to buy or
sell any security. Please read the note for the full disclaimer.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service
1142813 23-Oct-2020
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=80996433f9edeab2c6a7abbce06b298d&application_id=1142813&site_id=vwd&application_name=news
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=fe73645c3c876b5ce945e1fd0198c985&application_id=1142813&site_id=vwd&application_name=news
3: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=1142813&site_id=vwd&application_name=news
(END) Dow Jones Newswires
October 23, 2020 09:25 ET (13:25 GMT)
© 2020 Dow Jones News
